Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
August 29 2023 - 7:00AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
August
2023
Commission
File Number: 001-41386
OKYO
Pharma LTD
(Exact
Name of Registrant as Specified in Its Charter)
9th
Floor
107
Cheapside
London
EC2V
6DN
(Address
of registrant’s principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K
On
August 29, 2023, OKYO Pharma LTD (the “Company”) issued this 6K announcing that, it received notification from the
Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying OKYO that it
has regained compliance with the minimum $35 million market value requirement for continued inclusion on the Nasdaq Capital Market pursuant
to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Rule”), a copy of which is furnished as Exhibit 99.1
The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly
set forth by specific reference in such a filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
OKYO
Pharma LTD |
|
|
|
Date:
August 29, 2023 |
By: |
/s/
Keeren Shah |
|
Name: |
Keeren
Shah |
|
Title: |
Chief
Financial Officer |
EXHIBIT
INDEX
Exhibit
99.1
OKYO
Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule
New
York and London, August 29, 2023 – OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”),
an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat
dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that it received notification
from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying OKYO
that it has regained compliance with the minimum $35 million market value requirement for continued inclusion on the Nasdaq Capital
Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Rule”).
OKYO
was previously notified by Nasdaq on July 26, 2023 that it was not in compliance with the minimum market value requirement rule (under
Rule 5550(b)(2)) because the market value of OKYO’s ordinary shares had closed below the minimum $35 million requirement for 30
consecutive business days. To regain compliance, the Company was required to maintain a market value of OKYO’s ordinary shares
at $35 million or more for a minimum of 10 consecutive business days, which was met on August 28, 2023.
About
OKYO
OKYO
Pharma Limited (Nasdaq: OKYO) is a life sciences company focusing on the discovery and development of novel molecules to treat inflammatory
dry eye diseases and chronic pain. For further information, please visit www.okyopharma.com.
Forward-Looking
Statements
Certain
statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather
are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words
such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ’seeks,’
‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees
of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s
control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking
statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to
release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events
occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For
further information, please visit the Company’s website at www.okyopharma.com
Enquiries:
OKYO
Pharma Limited |
Gary
S. Jacob, Chief Executive Officer |
U.S.
917-497-7560
|
|
|
|
Investor
Relations |
Paul
Spencer |
+44
(0)20 7495 2379 |
OKYO Pharma (NASDAQ:OKYO)
Historical Stock Chart
From Apr 2024 to May 2024
OKYO Pharma (NASDAQ:OKYO)
Historical Stock Chart
From May 2023 to May 2024